Evaluating Anti-Cancer Prescriptions

separator
Share:

 

CLIENT SITUATION
A healthcare team working on behalf of a pharmaceutical company wanted to better understand how anti-cancer pharmaceuticals are evaluated for inclusion on payer prescription lists. They were conducting strategy research and needed a large volume of experts across a variety of perspectives, including Pharmacy and Therapeutics (P&T) Committee members at Integrated Delivery Networks (IDNs), Commercial Payers, and Oncology Supergroups. They also needed to engage with Oncology Pathway Development Experts.

 

GUIDEPOINT SOLUTION
Guidepoint was able to build a plan with the client team to organize their various simultaneous work streams. They immediately began to custom recruit for Advisors with recent and relevant experience. The team was able to work with the client to pivot as their research developed and to maintain flexible timelines.
Examples of Advisors included:
  • 11 IDN Payers: Medical Directors and Pharmacy Directors
  • 2 Commercial Payers
  • 3 Oncology Supergroup Decision-Makers, including C-level executives
  • 3 Pathway Development Experts

 

RESULTS
The Guidepoint team fulfilled each bucket of the client’s request and delivered 19 relevant and knowledgeable Advisors. The client noted that their team was very happy with the calls, saying: “Thanks again for pushing hard on those profiles – our team has been able to gain a lot of important insights through the interviews!”

 

Need experts? Get started now.